オピオイド誘発性便秘治療薬の世界市場2020年：企業別、地域別、種類・用途別

• 英文タイトル：Global Opioid Induced Constipation Drugs Market 2020 by Company, Regions, Type and Application, Forecast to 2025

• レポートコード：MRC2012B0930 • 出版社/出版日：GlobalInfoResearch / 2020年12月24日 ※2025年版があります。お問い合わせください。 • レポート形態：英文、PDF、125ページ • 納品方法：Eメール（納期：2~3日） • 産業分類：医療、製薬

• 販売価格（消費税別）

Single User	￥522,000 (USD3,480)	▷ お問い合わせ
Multi User	￥783,000 (USD5,220)	▷ お問い合わせ
Corporate User	￥1,044,000 (USD6,960)	▷ お問い合わせ

• ご注文方法：お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法：銀行振込（納品後、ご請求書送付）

---

レポート概要

---

本調査レポートでは、オピオイド誘発性便秘治療薬の世界市場を広く調査・分析し、今後の市場展望をまとめております。オピオイド誘発性便秘治療薬の種類別市場規模（ルビプロストン、臭化メチルナルトレキソン、ナルデメジン、アルビモパン、その他）、用途別市場規模（病院薬局、小売薬局、オンライン薬局）、地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、中国、日本、東南アジア、南米、中東、アフリカなど）、市場動向、企業別販売量と市場シェアなどの情報を掲載しています。 ・市場概要 ・企業情報（販売量、市場シェア、製品概要、SWOT分析）：Ironwood Pharmaceuticals Inc、Purdue Pharma、Progenics Pharmaceuticals Inc、Daiichi Sankyo Co Ltd、Nektar Therapeutics、Pfizer、Mundipharma International Limited、Allergan Plc、Shionogi & Co., Ltd、S.L.A. Pharma AG、Cosmo Pharmaceuticals SA、Sucampo Pharmaceuticals、Ono Pharmaceutical Co., Ltd、Daewoong Pharmaceutical、Bausch Health、Takeda Pharmaceutical Company Limited、C.B. Fleet Company、Theravance Biopharma Inc、 ・地域別グローバル市場分析 2015年-2020年 ・オピオイド誘発性便秘治療薬の北米市場（アメリカ、カナダ、メキシコ） ・オピオイド誘発性便秘治療薬のヨーロッパ市場（ドイツ、イギリス、フランス、ロシア、イタリア） ・オピオイド誘発性便秘治療薬のアジア市場（中国、日本、韓国、インド、東南アジア、オーストラリア） ・オピオイド誘発性便秘治療薬の南米市場（ブラジル、アルゼンチン） ・オピオイド誘発性便秘治療薬の中東・アフリカ市場（サウジアラビア、トルコ、エジプト、南アフリカ） ・種類別分析：ルビプロストン、臭化メチルナルトレキソン、ナルデメジン、アルビモパン、その他 ・用途別分析：病院薬局、小売薬局、オンライン薬局 ・地域別市場規模予測 2021年-2025年 ・調査の結果・結論

Market Overview
The global Opioid Induced Constipation Drugs market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of xx% in the forecast period of 2020 to 2025 and will expected to reach USD xx million by 2025, from USD xx million in 2019.

The Opioid Induced Constipation Drugs market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.

Market segmentation
Opioid Induced Constipation Drugs market is split by Type and by Application. For the period 2015-2025, the growth among segments provide accurate calculations and forecasts for sales by Type and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.

By Type, Opioid Induced Constipation Drugs market has been segmented into:
Lubiprostone
Methyl Naltrexone Bromide
Naldemedine
Alvimopan
Other

By Application, Opioid Induced Constipation Drugs has been segmented into:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies

Regions and Countries Level Analysis
Regional analysis is another highly comprehensive part of the research and analysis study of the global Opioid Induced Constipation Drugs market presented in the report. This section sheds light on the sales growth of different regional and country-level Opioid Induced Constipation Drugs markets. For the historical and forecast period 2015 to 2025, it provides detailed and accurate country-wise volume analysis and region-wise market size analysis of the global Opioid Induced Constipation Drugs market.

The report offers in-depth assessment of the growth and other aspects of the Opioid Induced Constipation Drugs market in important countries (regions), including:
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia and Australia)
South America (Brazil, Argentina, Colombia)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)

Competitive Landscape and Opioid Induced Constipation Drugs Market Share Analysis
Opioid Induced Constipation Drugs competitive landscape provides details by vendors, including company overview, company total revenue (financials), market potential, global presence, Opioid Induced Constipation Drugs sales and revenue generated, market share, price, production sites and facilities, SWOT analysis, product launch. For the period 2015-2020, this study provides the Opioid Induced Constipation Drugs sales, revenue and market share for each player covered in this report.

The major players covered in Opioid Induced Constipation Drugs are:
Ironwood Pharmaceuticals Inc
Purdue Pharma
Progenics Pharmaceuticals Inc
Daiichi Sankyo Co Ltd
Nektar Therapeutics
Pfizer
Mundipharma International Limited
Allergan Plc
Shionogi & Co., Ltd
S.L.A. Pharma AG
Cosmo Pharmaceuticals SA
Sucampo Pharmaceuticals
Ono Pharmaceutical Co., Ltd
Daewoong Pharmaceutical
Bausch Health
Takeda Pharmaceutical Company Limited
C.B. Fleet Company
Theravance Biopharma Inc

レポート目次

---

Table of Contents

1 Opioid Induced Constipation Drugs Market Overview
1.1 Product Overview and Scope of Opioid Induced Constipation Drugs
1.2 Classification of Opioid Induced Constipation Drugs by Type
1.2.1 Global Opioid Induced Constipation Drugs Revenue by Type: 2015 VS 2019 VS 2025
1.2.2 Global Opioid Induced Constipation Drugs Revenue Market Share by Type in 2019
1.2.3 Lubiprostone
1.2.4 Methyl Naltrexone Bromide
1.2.5 Naldemedine
1.2.6 Alvimopan
1.2.7 Other
1.3 Global Opioid Induced Constipation Drugs Market by Application
1.3.1 Overview: Global Opioid Induced Constipation Drugs Revenue by Application: 2015 VS 2019 VS 2025
1.3.2 Hospital Pharmacies
1.3.3 Retail Pharmacies
1.3.4 Online Pharmacies
1.4 Global Opioid Induced Constipation Drugs Market by Regions
1.4.1 Global Opioid Induced Constipation Drugs Market Size by Regions: 2015 VS 2019 VS 2025
1.4.2 Global Market Size of Opioid Induced Constipation Drugs (2015-2025)
1.4.3 North America (USA, Canada and Mexico) Opioid Induced Constipation Drugs Status and Prospect (2015-2025)
1.4.4 Europe (Germany, France, UK, Russia and Italy) Opioid Induced Constipation Drugs Status and Prospect (2015-2025)
1.4.5 Asia-Pacific (China, Japan, Korea, India and Southeast Asia) Opioid Induced Constipation Drugs Status and Prospect (2015-2025)
1.4.6 South America (Brazil, Argentina, Colombia) Opioid Induced Constipation Drugs Status and Prospect (2015-2025)
1.4.7 Middle East & Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa) Opioid Induced Constipation Drugs Status and Prospect (2015-2025)
2 Company Profiles
2.1 Ironwood Pharmaceuticals Inc
2.1.1 Ironwood Pharmaceuticals Inc Details
2.1.2 Ironwood Pharmaceuticals Inc Major Business and Total Revenue (Financial Highlights) Analysis
2.1.3 Ironwood Pharmaceuticals Inc SWOT Analysis
2.1.4 Ironwood Pharmaceuticals Inc Product and Services
2.1.5 Ironwood Pharmaceuticals Inc Opioid Induced Constipation Drugs Revenue, Gross Margin and Market Share (2018-2019)
2.2 Purdue Pharma
2.2.1 Purdue Pharma Details
2.2.2 Purdue Pharma Major Business and Total Revenue (Financial Highlights) Analysis
2.2.3 Purdue Pharma SWOT Analysis
2.2.4 Purdue Pharma Product and Services
2.2.5 Purdue Pharma Opioid Induced Constipation Drugs Revenue, Gross Margin and Market Share (2018-2019)
2.3 Progenics Pharmaceuticals Inc
2.3.1 Progenics Pharmaceuticals Inc Details
2.3.2 Progenics Pharmaceuticals Inc Major Business and Total Revenue (Financial Highlights) Analysis
2.3.3 Progenics Pharmaceuticals Inc SWOT Analysis
2.3.4 Progenics Pharmaceuticals Inc Product and Services
2.3.5 Progenics Pharmaceuticals Inc Opioid Induced Constipation Drugs Revenue, Gross Margin and Market Share (2018-2019)
2.4 Daiichi Sankyo Co Ltd
2.4.1 Daiichi Sankyo Co Ltd Details
2.4.2 Daiichi Sankyo Co Ltd Major Business and Total Revenue (Financial Highlights) Analysis
2.4.3 Daiichi Sankyo Co Ltd SWOT Analysis
2.4.4 Daiichi Sankyo Co Ltd Product and Services
2.4.5 Daiichi Sankyo Co Ltd Opioid Induced Constipation Drugs Revenue, Gross Margin and Market Share (2018-2019)
2.5 Nektar Therapeutics
2.5.1 Nektar Therapeutics Details
2.5.2 Nektar Therapeutics Major Business and Total Revenue (Financial Highlights) Analysis
2.5.3 Nektar Therapeutics SWOT Analysis
2.5.4 Nektar Therapeutics Product and Services
2.5.5 Nektar Therapeutics Opioid Induced Constipation Drugs Revenue, Gross Margin and Market Share (2018-2019)
2.6 Pfizer
2.6.1 Pfizer Details
2.6.2 Pfizer Major Business and Total Revenue (Financial Highlights) Analysis
2.6.3 Pfizer SWOT Analysis
2.6.4 Pfizer Product and Services
2.6.5 Pfizer Opioid Induced Constipation Drugs Revenue, Gross Margin and Market Share (2018-2019)
2.7 Mundipharma International Limited
2.7.1 Mundipharma International Limited Details
2.7.2 Mundipharma International Limited Major Business and Total Revenue (Financial Highlights) Analysis
2.7.3 Mundipharma International Limited SWOT Analysis
2.7.4 Mundipharma International Limited Product and Services
2.7.5 Mundipharma International Limited Opioid Induced Constipation Drugs Revenue, Gross Margin and Market Share (2018-2019)
2.8 Allergan Plc
2.8.1 Allergan Plc Details
2.8.2 Allergan Plc Major Business and Total Revenue (Financial Highlights) Analysis
2.8.3 Allergan Plc SWOT Analysis
2.8.4 Allergan Plc Product and Services
2.8.5 Allergan Plc Opioid Induced Constipation Drugs Revenue, Gross Margin and Market Share (2018-2019)
2.9 Shionogi & Co., Ltd
2.9.1 Shionogi & Co., Ltd Details
2.9.2 Shionogi & Co., Ltd Major Business and Total Revenue (Financial Highlights) Analysis
2.9.3 Shionogi & Co., Ltd SWOT Analysis
2.9.4 Shionogi & Co., Ltd Product and Services
2.9.5 Shionogi & Co., Ltd Opioid Induced Constipation Drugs Revenue, Gross Margin and Market Share (2018-2019)
2.10 S.L.A. Pharma AG
2.10.1 S.L.A. Pharma AG Details
2.10.2 S.L.A. Pharma AG Major Business and Total Revenue (Financial Highlights) Analysis
2.10.3 S.L.A. Pharma AG SWOT Analysis
2.10.4 S.L.A. Pharma AG Product and Services
2.10.5 S.L.A. Pharma AG Opioid Induced Constipation Drugs Revenue, Gross Margin and Market Share (2018-2019)
2.11 Cosmo Pharmaceuticals SA
2.11.1 Cosmo Pharmaceuticals SA Details
2.11.2 Cosmo Pharmaceuticals SA Major Business and Total Revenue (Financial Highlights) Analysis
2.11.3 Cosmo Pharmaceuticals SA SWOT Analysis
2.11.4 Cosmo Pharmaceuticals SA Product and Services
2.11.5 Cosmo Pharmaceuticals SA Opioid Induced Constipation Drugs Revenue, Gross Margin and Market Share (2018-2019)
2.12 Sucampo Pharmaceuticals
2.12.1 Sucampo Pharmaceuticals Details
2.12.2 Sucampo Pharmaceuticals Major Business and Total Revenue (Financial Highlights) Analysis
2.12.3 Sucampo Pharmaceuticals SWOT Analysis
2.12.4 Sucampo Pharmaceuticals Product and Services
2.12.5 Sucampo Pharmaceuticals Opioid Induced Constipation Drugs Revenue, Gross Margin and Market Share (2018-2019)
2.13 Ono Pharmaceutical Co., Ltd
2.13.1 Ono Pharmaceutical Co., Ltd Details
2.13.2 Ono Pharmaceutical Co., Ltd Major Business and Total Revenue (Financial Highlights) Analysis
2.13.3 Ono Pharmaceutical Co., Ltd SWOT Analysis
2.13.4 Ono Pharmaceutical Co., Ltd Product and Services
2.13.5 Ono Pharmaceutical Co., Ltd Opioid Induced Constipation Drugs Revenue, Gross Margin and Market Share (2018-2019)
2.14 Daewoong Pharmaceutical
2.14.1 Daewoong Pharmaceutical Details
2.14.2 Daewoong Pharmaceutical Major Business and Total Revenue (Financial Highlights) Analysis
2.14.3 Daewoong Pharmaceutical SWOT Analysis
2.14.4 Daewoong Pharmaceutical Product and Services
2.14.5 Daewoong Pharmaceutical Opioid Induced Constipation Drugs Revenue, Gross Margin and Market Share (2018-2019)
2.15 Bausch Health
2.15.1 Bausch Health Details
2.15.2 Bausch Health Major Business and Total Revenue (Financial Highlights) Analysis
2.15.3 Bausch Health SWOT Analysis
2.15.4 Bausch Health Product and Services
2.15.5 Bausch Health Opioid Induced Constipation Drugs Revenue, Gross Margin and Market Share (2018-2019)
2.16 Takeda Pharmaceutical Company Limited
2.16.1 Takeda Pharmaceutical Company Limited Details
2.16.2 Takeda Pharmaceutical Company Limited Major Business and Total Revenue (Financial Highlights) Analysis
2.16.3 Takeda Pharmaceutical Company Limited SWOT Analysis
2.16.4 Takeda Pharmaceutical Company Limited Product and Services
2.16.5 Takeda Pharmaceutical Company Limited Opioid Induced Constipation Drugs Revenue, Gross Margin and Market Share (2018-2019)
2.17 C.B. Fleet Company
2.17.1 C.B. Fleet Company Details
2.17.2 C.B. Fleet Company Major Business and Total Revenue (Financial Highlights) Analysis
2.17.3 C.B. Fleet Company SWOT Analysis
2.17.4 C.B. Fleet Company Product and Services
2.17.5 C.B. Fleet Company Opioid Induced Constipation Drugs Revenue, Gross Margin and Market Share (2018-2019)
2.18 Theravance Biopharma Inc
2.18.1 Theravance Biopharma Inc Details
2.18.2 Theravance Biopharma Inc Major Business and Total Revenue (Financial Highlights) Analysis
2.18.3 Theravance Biopharma Inc SWOT Analysis
2.18.4 Theravance Biopharma Inc Product and Services
2.18.3 Theravance Biopharma Inc Opioid Induced Constipation Drugs Revenue, Gross Margin and Market Share (2018-2019)
3 Market Competition, by Players
3.1 Global Opioid Induced Constipation Drugs Revenue and Share by Players (2015-2020)
3.2 Market Concentration Rate
3.2.1 Top 5 Opioid Induced Constipation Drugs Players Market Share
3.2.2 Top 10 Opioid Induced Constipation Drugs Players Market Share
3.3 Market Competition Trend
4 Market Size by Regions
4.1 Global Opioid Induced Constipation Drugs Revenue and Market Share by Regions
4.2 North America Opioid Induced Constipation Drugs Revenue and Growth Rate (2015-2020)
4.3 Europe Opioid Induced Constipation Drugs Revenue and Growth Rate (2015-2020)
4.4 Asia-Pacific Opioid Induced Constipation Drugs Revenue and Growth Rate (2015-2020)
4.5 South America Opioid Induced Constipation Drugs Revenue and Growth Rate (2015-2020)
4.6 Middle East & Africa Opioid Induced Constipation Drugs Revenue and Growth Rate (2015-2020)
5 North America Opioid Induced Constipation Drugs Revenue by Countries
5.1 North America Opioid Induced Constipation Drugs Revenue by Countries (2015-2020)
5.2 USA Opioid Induced Constipation Drugs Revenue and Growth Rate (2015-2020)
5.3 Canada Opioid Induced Constipation Drugs Revenue and Growth Rate (2015-2020)
5.4 Mexico Opioid Induced Constipation Drugs Revenue and Growth Rate (2015-2020)
6 Europe Opioid Induced Constipation Drugs Revenue by Countries
6.1 Europe Opioid Induced Constipation Drugs Revenue by Countries (2015-2020)
6.2 Germany Opioid Induced Constipation Drugs Revenue and Growth Rate (2015-2020)
6.3 UK Opioid Induced Constipation Drugs Revenue and Growth Rate (2015-2020)
6.4 France Opioid Induced Constipation Drugs Revenue and Growth Rate (2015-2020)
6.5 Russia Opioid Induced Constipation Drugs Revenue and Growth Rate (2015-2020)
6.6 Italy Opioid Induced Constipation Drugs Revenue and Growth Rate (2015-2020)
7 Asia-Pacific Opioid Induced Constipation Drugs Revenue by Countries
7.1 Asia-Pacific Opioid Induced Constipation Drugs Revenue by Countries (2015-2020)
7.2 China Opioid Induced Constipation Drugs Revenue and Growth Rate (2015-2020)
7.3 Japan Opioid Induced Constipation Drugs Revenue and Growth Rate (2015-2020)
7.4 Korea Opioid Induced Constipation Drugs Revenue and Growth Rate (2015-2020)
7.5 India Opioid Induced Constipation Drugs Revenue and Growth Rate (2015-2020)
7.6 Southeast Asia Opioid Induced Constipation Drugs Revenue and Growth Rate (2015-2020)
8 South America Opioid Induced Constipation Drugs Revenue by Countries
8.1 South America Opioid Induced Constipation Drugs Revenue by Countries (2015-2020)
8.2 Brazil Opioid Induced Constipation Drugs Revenue and Growth Rate (2015-2020)
8.3 Argentina Opioid Induced Constipation Drugs Revenue and Growth Rate (2015-2020)
9 Middle East & Africa Revenue Opioid Induced Constipation Drugs by Countries
9.1 Middle East & Africa Opioid Induced Constipation Drugs Revenue by Countries (2015-2020)
9.2 Saudi Arabia Opioid Induced Constipation Drugs Revenue and Growth Rate (2015-2020)
9.3 UAE Opioid Induced Constipation Drugs Revenue and Growth Rate (2015-2020)
9.4 Egypt Opioid Induced Constipation Drugs Revenue and Growth Rate (2015-2020)
9.5 South Africa Opioid Induced Constipation Drugs Revenue and Growth Rate (2015-2020)
10 Market Size Segment by Type
10.1 Global Opioid Induced Constipation Drugs Revenue and Market Share by Type (2015-2020)
10.2 Global Opioid Induced Constipation Drugs Market Forecast by Type (2019-2024)
10.3 Lubiprostone Revenue Growth Rate (2015-2025)
10.4 Methyl Naltrexone Bromide Revenue Growth Rate (2015-2025)
10.5 Naldemedine Revenue Growth Rate (2015-2025)
10.6 Alvimopan Revenue Growth Rate (2015-2025)
10.7 Other Revenue Growth Rate (2015-2025)
11 Global Opioid Induced Constipation Drugs Market Segment by Application
11.1 Global Opioid Induced Constipation Drugs Revenue Market Share by Application (2015-2020)
11.2 Opioid Induced Constipation Drugs Market Forecast by Application (2019-2024)
11.3 Hospital Pharmacies Revenue Growth (2015-2020)
11.4 Retail Pharmacies Revenue Growth (2015-2020)
11.5 Online Pharmacies Revenue Growth (2015-2020)
12 Global Opioid Induced Constipation Drugs Market Size Forecast (2021-2025)
12.1 Global Opioid Induced Constipation Drugs Market Size Forecast (2021-2025)
12.2 Global Opioid Induced Constipation Drugs Market Forecast by Regions (2021-2025)
12.3 North America Opioid Induced Constipation Drugs Revenue Market Forecast (2021-2025)
12.4 Europe Opioid Induced Constipation Drugs Revenue Market Forecast (2021-2025)
12.5 Asia-Pacific Opioid Induced Constipation Drugs Revenue Market Forecast (2021-2025)
12.6 South America Opioid Induced Constipation Drugs Revenue Market Forecast (2021-2025)
12.7 Middle East & Africa Opioid Induced Constipation Drugs Revenue Market Forecast (2021-2025)
13 Research Findings and Conclusion
14 Appendix
14.1 Methodology
14.2 Data Source
14.3 Disclaimer
14.4 About US

List of Tables

Table 1. Global Opioid Induced Constipation Drugs Revenue (USD Million) by Type: 2015 VS 2019 VS 2025
Table 2. Breakdown of Opioid Induced Constipation Drugs by Company Type (Tier 1, Tier 2 and Tier 3)
Table 3. Global Opioid Induced Constipation Drugs Revenue (USD Million) by Application: 2015 VS 2019 VS 2025
Table 4. Global Market Opioid Induced Constipation Drugs Revenue (Million USD) Comparison by Regions 2015-2025
Table 5. Ironwood Pharmaceuticals Inc Corporate Information, Location and Competitors
Table 6. Ironwood Pharmaceuticals Inc Opioid Induced Constipation Drugs Major Business
Table 7. Ironwood Pharmaceuticals Inc Opioid Induced Constipation Drugs Total Revenue (USD Million) (2017-2018)
Table 8. Ironwood Pharmaceuticals Inc SWOT Analysis
Table 9. Ironwood Pharmaceuticals Inc Opioid Induced Constipation Drugs Product and Solutions
Table 10. Ironwood Pharmaceuticals Inc Opioid Induced Constipation Drugs Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 11. Purdue Pharma Corporate Information, Location and Competitors
Table 12. Purdue Pharma Opioid Induced Constipation Drugs Major Business
Table 13. Purdue Pharma Opioid Induced Constipation Drugs Total Revenue (USD Million) (2018-2019)
Table 14. Purdue Pharma SWOT Analysis
Table 15. Purdue Pharma Opioid Induced Constipation Drugs Product and Solutions
Table 16. Purdue Pharma Opioid Induced Constipation Drugs Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 17. Progenics Pharmaceuticals Inc Corporate Information, Location and Competitors
Table 18. Progenics Pharmaceuticals Inc Opioid Induced Constipation Drugs Major Business
Table 19. Progenics Pharmaceuticals Inc Opioid Induced Constipation Drugs Total Revenue (USD Million) (2017-2018)
Table 20. Progenics Pharmaceuticals Inc SWOT Analysis
Table 21. Progenics Pharmaceuticals Inc Opioid Induced Constipation Drugs Product and Solutions
Table 22. Progenics Pharmaceuticals Inc Opioid Induced Constipation Drugs Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 23. Daiichi Sankyo Co Ltd Corporate Information, Location and Competitors
Table 24. Daiichi Sankyo Co Ltd Opioid Induced Constipation Drugs Major Business
Table 25. Daiichi Sankyo Co Ltd Opioid Induced Constipation Drugs Total Revenue (USD Million) (2017-2018)
Table 26. Daiichi Sankyo Co Ltd SWOT Analysis
Table 27. Daiichi Sankyo Co Ltd Opioid Induced Constipation Drugs Product and Solutions
Table 28. Daiichi Sankyo Co Ltd Opioid Induced Constipation Drugs Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 29. Nektar Therapeutics Corporate Information, Location and Competitors
Table 30. Nektar Therapeutics Opioid Induced Constipation Drugs Major Business
Table 31. Nektar Therapeutics Opioid Induced Constipation Drugs Total Revenue (USD Million) (2017-2018)
Table 32. Nektar Therapeutics SWOT Analysis
Table 33. Nektar Therapeutics Opioid Induced Constipation Drugs Product and Solutions
Table 34. Nektar Therapeutics Opioid Induced Constipation Drugs Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 35. Pfizer Corporate Information, Location and Competitors
Table 36. Pfizer Opioid Induced Constipation Drugs Major Business
Table 37. Pfizer Opioid Induced Constipation Drugs Total Revenue (USD Million) (2017-2018)
Table 38. Pfizer SWOT Analysis
Table 39. Pfizer Opioid Induced Constipation Drugs Product and Solutions
Table 40. Pfizer Opioid Induced Constipation Drugs Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 41. Mundipharma International Limited Corporate Information, Location and Competitors
Table 42. Mundipharma International Limited Opioid Induced Constipation Drugs Major Business
Table 43. Mundipharma International Limited Opioid Induced Constipation Drugs Total Revenue (USD Million) (2017-2018)
Table 44. Mundipharma International Limited SWOT Analysis
Table 45. Mundipharma International Limited Opioid Induced Constipation Drugs Product and Solutions
Table 46. Mundipharma International Limited Opioid Induced Constipation Drugs Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 47. Allergan Plc Corporate Information, Location and Competitors
Table 48. Allergan Plc Opioid Induced Constipation Drugs Major Business
Table 49. Allergan Plc Opioid Induced Constipation Drugs Total Revenue (USD Million) (2017-2018)
Table 50. Allergan Plc SWOT Analysis
Table 51. Allergan Plc Opioid Induced Constipation Drugs Product and Solutions
Table 52. Allergan Plc Opioid Induced Constipation Drugs Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 53. Shionogi & Co., Ltd Corporate Information, Location and Competitors
Table 54. Shionogi & Co., Ltd Opioid Induced Constipation Drugs Major Business
Table 55. Shionogi & Co., Ltd Opioid Induced Constipation Drugs Total Revenue (USD Million) (2017-2018)
Table 56. Shionogi & Co., Ltd SWOT Analysis
Table 57. Shionogi & Co., Ltd Opioid Induced Constipation Drugs Product and Solutions
Table 58. Shionogi & Co., Ltd Opioid Induced Constipation Drugs Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 59. S.L.A. Pharma AG Corporate Information, Location and Competitors
Table 60. S.L.A. Pharma AG Opioid Induced Constipation Drugs Major Business
Table 61. S.L.A. Pharma AG Opioid Induced Constipation Drugs Total Revenue (USD Million) (2017-2018)
Table 62. S.L.A. Pharma AG SWOT Analysis
Table 63. S.L.A. Pharma AG Opioid Induced Constipation Drugs Product and Solutions
Table 64. S.L.A. Pharma AG Opioid Induced Constipation Drugs Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 65. Cosmo Pharmaceuticals SA Corporate Information, Location and Competitors
Table 66. Cosmo Pharmaceuticals SA Opioid Induced Constipation Drugs Major Business
Table 67. Cosmo Pharmaceuticals SA Opioid Induced Constipation Drugs Total Revenue (USD Million) (2017-2018)
Table 68. Cosmo Pharmaceuticals SA SWOT Analysis
Table 69. Cosmo Pharmaceuticals SA Opioid Induced Constipation Drugs Product and Solutions
Table 70. Cosmo Pharmaceuticals SA Opioid Induced Constipation Drugs Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 71. Sucampo Pharmaceuticals Corporate Information, Location and Competitors
Table 72. Sucampo Pharmaceuticals Opioid Induced Constipation Drugs Major Business
Table 73. Sucampo Pharmaceuticals Opioid Induced Constipation Drugs Total Revenue (USD Million) (2017-2018)
Table 74. Sucampo Pharmaceuticals SWOT Analysis
Table 75. Sucampo Pharmaceuticals Opioid Induced Constipation Drugs Product and Solutions
Table 76. Sucampo Pharmaceuticals Opioid Induced Constipation Drugs Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 77. Ono Pharmaceutical Co., Ltd Corporate Information, Location and Competitors
Table 78. Ono Pharmaceutical Co., Ltd Opioid Induced Constipation Drugs Major Business
Table 79. Ono Pharmaceutical Co., Ltd Opioid Induced Constipation Drugs Total Revenue (USD Million) (2017-2018)
Table 80. Ono Pharmaceutical Co., Ltd SWOT Analysis
Table 81. Ono Pharmaceutical Co., Ltd Opioid Induced Constipation Drugs Product and Solutions
Table 82. Ono Pharmaceutical Co., Ltd Opioid Induced Constipation Drugs Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 83. Daewoong Pharmaceutical Corporate Information, Location and Competitors
Table 84. Daewoong Pharmaceutical Opioid Induced Constipation Drugs Major Business
Table 85. Daewoong Pharmaceutical Opioid Induced Constipation Drugs Total Revenue (USD Million) (2017-2018)
Table 86. Daewoong Pharmaceutical SWOT Analysis
Table 87. Daewoong Pharmaceutical Opioid Induced Constipation Drugs Product and Solutions
Table 88. Daewoong Pharmaceutical Opioid Induced Constipation Drugs Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 89. Bausch Health Corporate Information, Location and Competitors
Table 90. Bausch Health Opioid Induced Constipation Drugs Major Business
Table 91. Bausch Health Opioid Induced Constipation Drugs Total Revenue (USD Million) (2017-2018)
Table 92. Bausch Health SWOT Analysis
Table 93. Bausch Health Opioid Induced Constipation Drugs Product and Solutions
Table 94. Bausch Health Opioid Induced Constipation Drugs Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 95. Takeda Pharmaceutical Company Limited Corporate Information, Location and Competitors
Table 96. Takeda Pharmaceutical Company Limited Opioid Induced Constipation Drugs Major Business
Table 97. Takeda Pharmaceutical Company Limited Opioid Induced Constipation Drugs Total Revenue (USD Million) (2017-2018)
Table 98. Takeda Pharmaceutical Company Limited SWOT Analysis
Table 99. Takeda Pharmaceutical Company Limited Opioid Induced Constipation Drugs Product and Solutions
Table 100. Takeda Pharmaceutical Company Limited Opioid Induced Constipation Drugs Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 101. C.B. Fleet Company Corporate Information, Location and Competitors
Table 102. C.B. Fleet Company Opioid Induced Constipation Drugs Major Business
Table 103. C.B. Fleet Company Opioid Induced Constipation Drugs Total Revenue (USD Million) (2017-2018)
Table 104. C.B. Fleet Company SWOT Analysis
Table 105. C.B. Fleet Company Opioid Induced Constipation Drugs Product and Solutions
Table 106. C.B. Fleet Company Opioid Induced Constipation Drugs Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 107. Theravance Biopharma Inc Opioid Induced Constipation Drugs Type and Application
Table 108. Theravance Biopharma Inc Opioid Induced Constipation Drugs Major Business
Table 109. Theravance Biopharma Inc Opioid Induced Constipation Drugs Total Revenue (USD Million) (2017-2018)
Table 110. Theravance Biopharma Inc SWOT Analysis
Table 111. Theravance Biopharma Inc Opioid Induced Constipation Drugs Product and Solutions
Table 112. Theravance Biopharma Inc Opioid Induced Constipation Drugs Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 113. Global Opioid Induced Constipation Drugs Revenue (Million USD) by Players (2015-2020)
Table 114. Global Opioid Induced Constipation Drugs Revenue Share by Players (2015-2020)
Table 115. Global Opioid Induced Constipation Drugs Revenue (Million USD) by Regions (2015-2020)
Table 116. Global Opioid Induced Constipation Drugs Revenue Market Share by Regions (2015-2020)
Table 117. North America Opioid Induced Constipation Drugs Revenue by Countries (2015-2020)
Table 118. North America Opioid Induced Constipation Drugs Revenue Market Share by Countries (2015-2020)
Table 119. Europe Opioid Induced Constipation Drugs Revenue (Million USD) by Countries (2015-2020)
Table 120. Asia-Pacific Opioid Induced Constipation Drugs Revenue (Million USD) by Countries (2015-2020)
Table 121. South America Opioid Induced Constipation Drugs Revenue by Countries (2015-2020)
Table 122. South America Opioid Induced Constipation Drugs Revenue Market Share by Countries (2015-2020)
Table 123. Middle East and Africa Opioid Induced Constipation Drugs Revenue (Million USD) by Countries (2015-2020)
Table 124. Middle East and Africa Opioid Induced Constipation Drugs Revenue Market Share by Countries (2015-2020)
Table 125. Global Opioid Induced Constipation Drugs Revenue (Million USD) by Type (2015-2020)
Table 126. Global Opioid Induced Constipation Drugs Revenue Share by Type (2015-2020)
Table 127. Global Opioid Induced Constipation Drugs Revenue Forecast by Type (2021-2025)
Table 128. Global Opioid Induced Constipation Drugs Revenue by Application (2015-2020)
Table 129. Global Opioid Induced Constipation Drugs Revenue Share by Application (2015-2020)
Table 130. Global Opioid Induced Constipation Drugs Revenue Forecast by Application (2021-2025)
Table 131. Global Opioid Induced Constipation Drugs Revenue (Million USD) Forecast by Regions (2021-2025)
List of Figures
Figure 1. Opioid Induced Constipation Drugs Picture
Figure 2. Global Opioid Induced Constipation Drugs Revenue Market Share by Type in 2019
Figure 3. Lubiprostone Picture
Figure 4. Methyl Naltrexone Bromide Picture
Figure 5. Naldemedine Picture
Figure 6. Alvimopan Picture
Figure 7. Other Picture
Figure 8. Opioid Induced Constipation Drugs Revenue Market Share by Application in 2019
Figure 9. Hospital Pharmacies Picture
Figure 10. Retail Pharmacies Picture
Figure 11. Online Pharmacies Picture
Figure 12. Global Opioid Induced Constipation Drugs Revenue (USD Million) and Growth Rate (2015-2025)
Figure 13. North America Opioid Induced Constipation Drugs Revenue (Million USD) and Growth Rate (2015-2025)
Figure 14. Europe Opioid Induced Constipation Drugs Revenue (Million USD) and Growth Rate (2015-2025)
Figure 15. Asia-Pacific Opioid Induced Constipation Drugs Revenue (Million USD) and Growth Rate (2015-2025)
Figure 16. South America Opioid Induced Constipation Drugs Revenue (Million USD) and Growth Rate (2015-2025)
Figure 17. Middle East and Africa Opioid Induced Constipation Drugs Revenue (Million USD) and Growth Rate (2015-2025)
Figure 18. Global Opioid Induced Constipation Drugs Revenue (Million USD) and Growth Rate (2015-2025)
Figure 19. Global Opioid Induced Constipation Drugs Revenue Share by Players in 2019
Figure 20. Global Top 5 Players Opioid Induced Constipation Drugs Revenue Market Share in 2019
Figure 21. Global Top 10 Players Opioid Induced Constipation Drugs Revenue Market Share in 2019
Figure 22. Key Players Market Share Trend
Figure 23. Global Opioid Induced Constipation Drugs Revenue (Million USD) and Growth Rate (%) (2015-2020)
Figure 24. Global Opioid Induced Constipation Drugs Revenue Market Share by Regions (2015-2020)
Figure 25. Global Opioid Induced Constipation Drugs Revenue Market Share by Regions in 2018
Figure 26. North America Opioid Induced Constipation Drugs Revenue and Growth Rate (2015-2020)
Figure 27. Europe Opioid Induced Constipation Drugs Revenue and Growth Rate (2015-2020)
Figure 28. Asia-Pacific Opioid Induced Constipation Drugs Revenue and Growth Rate (2015-2020)
Figure 29. South America Opioid Induced Constipation Drugs Revenue and Growth Rate (2015-2020)
Figure 30. Middle East and Africa Opioid Induced Constipation Drugs Revenue and Growth Rate (2015-2020)
Figure 31. North America Opioid Induced Constipation Drugs Revenue Market Share by Countries (2015-2020)
Figure 32. North America Opioid Induced Constipation Drugs Revenue Market Share by Countries in 2019
Figure 33. USA Opioid Induced Constipation Drugs Revenue and Growth Rate (2015-2020)
Figure 34. Canada Opioid Induced Constipation Drugs Revenue and Growth Rate (2015-2020)
Figure 35. Mexico Opioid Induced Constipation Drugs Revenue and Growth Rate (2015-2020)
Figure 36. Europe Opioid Induced Constipation Drugs Revenue Market Share by Countries (2015-2020)
Figure 37. Europe Opioid Induced Constipation Drugs Revenue Market Share by Countries in 2019
Figure 38. Germany Opioid Induced Constipation Drugs Revenue and Growth Rate (2015-2020)
Figure 39. UK Opioid Induced Constipation Drugs Revenue and Growth Rate (2015-2020)
Figure 40. France Opioid Induced Constipation Drugs Revenue and Growth Rate (2015-2020)
Figure 41. Russia Opioid Induced Constipation Drugs Revenue and Growth Rate (2015-2020)
Figure 42. Italy Opioid Induced Constipation Drugs Revenue and Growth Rate (2015-2020)
Figure 43. Asia-Pacific Opioid Induced Constipation Drugs Revenue Market Share by Countries (2015-2020)
Figure 44. Asia-Pacific Opioid Induced Constipation Drugs Revenue Market Share by Countries in 2019
Figure 45. China Opioid Induced Constipation Drugs Revenue and Growth Rate (2015-2020)
Figure 46. Japan Opioid Induced Constipation Drugs Revenue and Growth Rate (2015-2020)
Figure 47. Korea Opioid Induced Constipation Drugs Revenue and Growth Rate (2015-2020)
Figure 48. India Opioid Induced Constipation Drugs Revenue and Growth Rate (2015-2020)
Figure 49. Southeast Asia Opioid Induced Constipation Drugs Revenue and Growth Rate (2015-2020)
Figure 50. South America Opioid Induced Constipation Drugs Revenue Market Share by Countries (2015-2020)
Figure 51. South America Opioid Induced Constipation Drugs Revenue Market Share by Countries in 2019
Figure 52. Brazil Opioid Induced Constipation Drugs Revenue and Growth Rate (2015-2020)
Figure 53. Argentina Opioid Induced Constipation Drugs Revenue and Growth Rate (2015-2020)
Figure 54. Middle East and Africa Opioid Induced Constipation Drugs Revenue Market Share by Countries (2015-2020)
Figure 55. Middle East and Africa Opioid Induced Constipation Drugs Revenue Market Share by Countries in 2019
Figure 56. Saudi Arabia Opioid Induced Constipation Drugs Revenue and Growth Rate (2015-2020)
Figure 57. UAE Opioid Induced Constipation Drugs Revenue and Growth Rate (2015-2020)
Figure 58. Egypt Opioid Induced Constipation Drugs Revenue and Growth Rate (2015-2020)
Figure 59. South Africa Opioid Induced Constipation Drugs Revenue and Growth Rate (2015-2020)
Figure 60. Global Opioid Induced Constipation Drugs Revenue Share by Type (2015-2020)
Figure 61. Global Opioid Induced Constipation Drugs Revenue Share by Type in 2019
Figure 62. Global Opioid Induced Constipation Drugs Market Share Forecast by Type (2021-2025)
Figure 63. Global Lubiprostone Revenue Growth Rate (2015-2020)
Figure 64. Global Methyl Naltrexone Bromide Revenue Growth Rate (2015-2020)
Figure 65. Global Naldemedine Revenue Growth Rate (2015-2020)
Figure 66. Global Alvimopan Revenue Growth Rate (2015-2020)
Figure 67. Global Other Revenue Growth Rate (2015-2020)
Figure 68. Global Opioid Induced Constipation Drugs Revenue Share by Application (2015-2020)
Figure 69. Global Opioid Induced Constipation Drugs Revenue Share by Application in 2019
Figure 70. Global Opioid Induced Constipation Drugs Market Share Forecast by Application (2021-2025)
Figure 71. Global Hospital Pharmacies Revenue Growth Rate (2015-2020)
Figure 72. Global Retail Pharmacies Revenue Growth Rate (2015-2020)
Figure 73. Global Online Pharmacies Revenue Growth Rate (2015-2020)
Figure 74. Global Opioid Induced Constipation Drugs Revenue (Million USD) and Growth Rate Forecast (2021-2025)
Figure 75. Global Opioid Induced Constipation Drugs Revenue (Million USD) Forecast by Regions (2021-2025)
Figure 76. Global Opioid Induced Constipation Drugs Revenue Market Share Forecast by Regions (2021-2025)
Figure 77. North America Opioid Induced Constipation Drugs Revenue Market Forecast (2021-2025)
Figure 78. Europe Opioid Induced Constipation Drugs Revenue Market Forecast (2021-2025)
Figure 79. Asia-Pacific Opioid Induced Constipation Drugs Revenue Market Forecast (2021-2025)
Figure 80. South America Opioid Induced Constipation Drugs Revenue Market Forecast (2021-2025)
Figure 81. Middle East and Africa Opioid Induced Constipation Drugs Revenue Market Forecast (2021-2025)
Figure 82. Sales Channel: Direct Channel vs Indirect Channel

---